Massive mpox vaccine trial launches in DRC: could it stop the outbreak?
NCT ID NCT07093489
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This large study will test the LC16m8 mpox vaccine in nearly 12,000 people aged one year and older in the Democratic Republic of Congo. Researchers want to see if the vaccine can prevent mpox disease and monitor its safety. Participants will receive the vaccine as part of the government's rollout, and the study will compare infection rates between vaccinated and unvaccinated groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LC16m8 mpox vaccine
What this could lead to
If successful, this could provide a safe and effective vaccine to protect against mpox in both children and adults.
What could go wrong
This is a real-world study, not a controlled lab trial, so results may be less clear. The vaccine may not reach the hoped-for 70% protection, and safety in young children or pregnant women is not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MPOX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Institut National de la Recherche Biomédicale (INRB)
Kinshasa, Democratic Republic of the Congo
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact